@article{b37207f9ca8c4b218ee5eff57599b544,
title = "Laparoscopic Surgery for Acute Diffuse Peritonitis Due to Gastrointestinal Perforation: A Nationwide Epidemiologic Study Using the National Clinical Database",
abstract = "Background: Elective laparoscopic surgery is now widely accepted in the treatment of abdominal diseases because of its minimal invasiveness and rapid postoperative recovery. It is also used in the emergency setting for the diagnosis and treatment of acute diffuse peritonitis regardless of the causative disease. However, the value of laparoscopy in acute diffuse peritonitis remains unclear. In this study we aimed to show trends in the use of laparoscopy over time and compare the real-world performance of laparoscopic surgery with that of open surgery for acute diffuse peritonitis due to gastrointestinal perforation. Methods: We extracted data from the National Clinical Database, a nationwide surgery registration system in Japan, for patients with a diagnosis of acute diffuse peritonitis due to gastroduodenal or colorectal perforation between 2016 and 2019. Trends in the use of laparoscopy over time were identified. Patient characteristics, laboratory findings, surgical findings, and postoperative complications were compared between laparoscopic surgery and open surgery. Results: Patients in poor condition and those with abnormal laboratory findings tended to undergo open surgery. Anesthesia time and operating time were longer for laparoscopic surgery in patients with gastroduodenal perforation but shorter in those with colorectal perforation. Fewer complications occurred in patients who underwent laparoscopic surgery. The number of institutions where laparoscopic surgery was performed and the proportion of the use of laparoscopy at each institution increased over time. Conclusion: The use of laparoscopy is becoming common in surgery for acute diffuse peritonitis due to gastrointestinal perforation. This approach may be a useful option for acute diffuse peritonitis.",
keywords = "emergency surgery, gastrointestinal perforation, laparoscopic surgery, peritonitis",
author = "Nobuaki Hoshino and Hideki Endo and Koya Hida and Hiraku Kumamaru and Hiroshi Hasegawa and Teruhide Ishigame and Yuko Kitagawa and Yoshihiro Kakeji and Hiroaki Miyata and Yoshiharu Sakai",
note = "Funding Information: Funding: This study was supported by a grant from the Japanese Society for Abdominal Emergency Medicine. Funding Information: Funding: This study was supported by a grant from the Japanese Society for Abdominal Emergency Medicine. Conflict of Interest: Hideki Endo has received research expenses or scholarship donations from the National Clinical Database. Hiraku Kumamaru has received speaker fees from Pfizer Japan Inc. and Johnson & Johnson KK, and consultation fees from Mitsubishi Tanabe Pharma Corp. Hiraku Kumamaru is affiliated with the Department of Healthcare Quality Assessment at the University of Tokyo, which is a social collaboration department supported by the National Clinical Database, Johnson & Johnson KK, and Nipro Corp. Yuko Kitagawa has received lecture fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., Otsuka Pharmaceutical Factory, Inc., Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Nippon Covidien Inc., AstraZeneca KK, Ethicon Inc., Bristol-Myers Squibb KK, and Olympus Corp. Yuko Kitagawa has received research expenses or scholarship donations from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Asahi Kasei Pharma Corp., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Tsumura & Co., Kaken Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., EA Pharma Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Medicon Inc Kyowa Hakkou Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Astellas Pharma Inc., Teijin Pharma Ltd., Nihon Pharmaceutical Co., Ltd., and Nippon Covidien Inc. Yuko Kitagawa is the endowed chair of Chugai Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd. Hiroaki Miyata is the endowed chair of the National Clinical Database, Johnson & Johnson KK, and Nipro Corp. For the remaining authors, none were declared. The funding for this study was provided by the Japanese Society for Abdominal Emergency Medicine. The funding source had no role in the design, practice, or analysis of this study. Approval of the Research Protocol by an Institutional Reviewer Board: The study was approved by the Ethics Committee of Kyoto University (approval number R2777). Informed Consent (if applicable): N/A. Registry and the Registration No. of the Study/Trial: Not registered. Animal Studies (if applicable): N/A. Publisher Copyright: {\textcopyright} 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterology.",
year = "2022",
month = may,
doi = "10.1002/ags3.12533",
language = "English",
volume = "6",
pages = "430--444",
journal = "Annals of Gastroenterological Surgery",
issn = "2475-0328",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",
}